强生(JNJ.US)1类新药在华获批临床拟开发治疗骨髓增殖性肿瘤

智通财经04-01

智通财经APP获悉，3月31日，中国国家药监局药品审评中心(CDE)官网公示显示，强生(JNJ.US)申报的1类新药JNJ-88549968注射液获批临床，拟开发治疗骨髓增殖性肿瘤。公开资料显示，这是强生在研的一款靶向CALRmut×CD3的双特异性T细胞重定向抗体。本次该产品在中国获批临床，意味着其即将开展针对骨髓增殖性肿瘤的临床研究。骨髓增殖性肿瘤(MPNs)是起源于造血干细胞(HSC)区域的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2624519326?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-01 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624519326","market":"hk","top_or_hot":-1,"title":"强生(JNJ.US)1类新药在华获批临床 拟开发治疗骨髓增殖性肿瘤","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，3月31日，中国国家药监局药品审评中心(CDE)官网公示显示，强生(JNJ.US)申报的1类新药JNJ-88549968注射液获批临床，拟开发治疗骨髓增殖性肿瘤。公开资料显示，这是强生在研的一款靶向CALRmut×CD3的双特异性T细胞重定向抗体。本次该产品在中国获批临床，意味着其即将开展针对骨髓增殖性肿瘤的临床研究。骨髓增殖性肿瘤(MPNs)是起源于造血干细胞(HSC)区域的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1424233.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>强生(JNJ.US)1类新药在华获批临床 拟开发治疗骨髓增殖性肿瘤</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n强生(JNJ.US)1类新药在华获批临床 拟开发治疗骨髓增殖性肿瘤\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-01 21:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1424233.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，3月31日，中国国家药监局药品审评中心(CDE)官网公示显示，强生(JNJ.US)申报的1类新药JNJ-88549968注射液获批临床，拟开发治疗骨髓增殖性肿瘤。公开资料显示，这是强生在研的一款靶向CALRmut×CD3的双特异性T细胞重定向抗体。本次该产品在中国获批临床，意味着其即将开展针对骨髓增殖性肿瘤的临床研究。骨髓增殖性肿瘤(MPNs)是起源于造血干细胞(HSC)区域的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1424233.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001440.SGD","symbol_name":"United Global Dividend Equity Fund A SGD Dist","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1424233.html","article_id":"2624519326","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624519326","pubTimestamp":1775048929,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，3月31日，中国国家药监局药品审评中心官网公示显示，强生申报的1类新药JNJ-88549968注射液获批临床，拟开发治疗骨髓增殖性肿瘤。本次该产品在中国获批临床，意味着其即将开展针对骨髓增殖性肿瘤的临床研究。据了解，JNJ-88549968是一种靶向CALRmut的T细胞重定向双特异性抗体，其通过清除MPN克隆发挥作用。研究人员认为，该产品有望研发成为用于治疗CALRmut MPN的新型双特异性T细胞重定向抗体。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","BK4559":"巴菲特持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","BK4550":"红杉资本持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4532":"文艺复兴科技持仓","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","BK4585":"ETF&股票定投概念","LU0058720904.USD":"联博国际健康护理基金A","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","JNJ":"强生"},"translate_title":"Johnson & Johnson (JNJ.US) Class 1 New Drug Approved in China for Clinical Development to Treat Myeloproliferative Tumors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1.5},"content_text":"智通财经APP获悉，3月31日，中国国家药监局药品审评中心(CDE)官网公示显示，强生(JNJ.US)申报的1类新药JNJ-88549968注射液获批临床，拟开发治疗骨髓增殖性肿瘤。公开资料显示，这是强生在研的一款靶向CALRmut×CD3的双特异性T细胞重定向抗体。本次该产品在中国获批临床，意味着其即将开展针对骨髓增殖性肿瘤的临床研究。骨髓增殖性肿瘤(MPNs)是起源于造血干细胞(HSC)区域的克隆性恶性造血系统疾病，其特征为髓系成熟血细胞的过度生成。研究表明，JAK2、血小板生成素受体(MPL)和钙网蛋白(CALR)的突变是MPN发病机制中的表型驱动因素。CALR突变(CALRmut)是MPN中第二常见的突变。CALRmut为插入或缺失突变，导致基因最后一个外显子发生移码，引起KDEL内质网滞留基序缺失，并产生一个由36个氨基酸组成的带正电荷的C端新抗原。由于KDEL基序的缺失，CALRmut不仅局限于内质网，而是通过与MPL相互作用转运至细胞表面，从而持续激活MPL并发挥致癌作用。T细胞参与的免疫疗法，如双特异性CD3重定向抗体，有望在临床上显示出令人期待的反应率。据了解，JNJ-88549968是一种靶向CALRmut的T细胞重定向双特异性抗体，其通过清除MPN克隆发挥作用。JNJ-88549968的作用机制是充当CALRmut MPN癌细胞与T细胞之间的桥梁，在体外和体内诱导T细胞活化，进而介导T细胞对CALRmut癌细胞的细胞毒性。临床前研究表明，JNJ-88549968可识别所有已知CALRmut类型中共有的CALRmut表位，显示出对CALRmut细胞系的选择性结合，与CALR野生型细胞无显著结合。该产品在体外可实现对CALRmut的选择性T细胞活化，并对经CALRmut改造的细胞系产生细胞毒性；可浓度依赖性地诱导患者来源的CALRmut CD34+细胞发生细胞毒性。针对所有检测的CALRmut CD34+癌细胞，均观察到JNJ-88549968介导的细胞毒性，且该作用与CALR突变类型无关。研究人员认为，该产品有望研发成为用于治疗CALRmut MPN的新型双特异性T细胞重定向抗体。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624519326","isCrawlerRequest":true}

强生(JNJ.US)1类新药在华获批临床 拟开发治疗骨髓增殖性肿瘤

精彩评论

强生(JNJ.US)1类新药在华获批临床拟开发治疗骨髓增殖性肿瘤